RT-3 (Retatrutide-Type) Triple Agonist: A Research Overview

RT-3 is our catalog name for a retatrutide-type peptide: a single molecule that activates three related receptors, the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon receptor (GCGR). In the scientific literature the compound is retatrutide, first described under the development code LY3437943 [5]. This overview covers the receptor biology behind the design, how the molecule is built, what the published rodent and clinical studies report, and what is still unresolved. Throughout, RT-3 refers to our research material and retatrutide to the compound as it was studied in the cited papers.

Three Receptors From One Hormone Family

GLP-1, GIP and glucagon are structurally related peptide hormones, and their receptors belong to the same class B G protein-coupled receptor family. That kinship is what makes a single hybrid agonist chemically possible. Each receptor, however, drives a different part of metabolic physiology.

GLP-1 receptor

GLP-1 is released from the gut within minutes of a meal. Activation of its receptor produces glucose-dependent insulin secretion, glucose-dependent inhibition of glucagon release, slower gastric emptying and satiety, and sustained GLP-1R activation has been associated with weight loss in both preclinical and clinical studies [10].

GIP receptor

GIP is the other incretin hormone. It shares GLP-1's glucose-dependent insulinotropic action on pancreatic beta cells through a structurally distinct but related receptor, and it also acts directly on adipose tissue, where it promotes energy storage [10]. In triple-agonist designs, the GIP component has been proposed to potentiate the incretin effect and to buffer against the glucose-raising action of the glucagon component, a role supported by loss-of-function experiments in rodents [2].

Glucagon receptor

Glucagon is best known for raising blood glucose [9], which made it an unlikely ingredient in a metabolic agonist. Over the past two decades, work with stable glucagon analogues has drawn attention to its less appreciated effects on lipids and body weight [9]. In diet-induced obese mice, a glucagon/GLP-1 co-agonist reduced body fat through a combination of decreased food intake and increased energy expenditure, and the degree of glucagon receptor agonism was a deliberate design variable [3].

Why Triple Agonism Is Studied

The rationale is complementary action on both sides of energy balance. GLP-1R and GIPR agonism act mainly on intake and on insulin secretion; GCGR agonism adds energy expenditure. In the foundational rodent work on a monomeric triagonist, genetic knockout, pharmacological blockade and selective chemical knockout each confirmed a contribution from every receptor. The authors attributed the overall effect predominantly to glucagon increasing energy expenditure, GLP-1 reducing caloric intake and improving glucose control, and GIP potentiating the incretin effect while offsetting glucagon's diabetogenic pull [2].

The discovery paper for LY3437943 reported the same pattern in obese mice: body-weight loss was augmented by GCGR-mediated increases in energy expenditure on top of the reduction in calorie intake driven by GIPR and GLP-1R [5]. The practical design question is therefore proportion. Glucagon activity carries an inherent diabetogenic pull that the other components must offset [2], so the balance between receptors matters as much as their number.

Structure and Design

Retatrutide was developed from a GIP peptide backbone. Cryo-electron microscopy structures of retatrutide bound to each of GLP-1R, GIPR and GCGR, published in 2024, show a set of conserved peptide–receptor contacts shared across all three receptors alongside receptor-specific conformations, particularly in extracellular loop 1, which together allow one sequence to activate all three [8]. The sequence includes non-coded amino acids, α-aminoisobutyric acid (Aib) and α-methyl-L-leucine, and carries a fatty diacid moiety attached through a linker to the lysine at position 17 [8].

Compared with the native hormones, retatrutide is reported to be about 8.9 times more potent at GIPR, and roughly 0.3 and 0.4 times as potent at GCGR and GLP-1R respectively [8]. The discovery paper describes the in-vitro profile as balanced GCGR and GLP-1R activity with more GIPR activity [5]. A triple agonist, in other words, is not an equal agonist, and potency ratios should be considered when interpreting any receptor-level result.

Acylation and half-life

Native GLP-1 and GIP are degraded rapidly by the enzyme dipeptidyl peptidase-4 [10], which is why long-acting analogues were developed. Fatty diacid acylation through a lysine-linked linker is shared by several incretin-class peptides, including semaglutide, tirzepatide and retatrutide [8]; in the tirzepatide discovery work it is described as enabling albumin binding, which extends circulating exposure [11]. For retatrutide, pharmacokinetics were dose proportional with a half-life of approximately 6 days in a 12-week phase 1b study in people with type 2 diabetes [6]. In the earlier single-ascending-dose study, body-weight reduction persisted up to day 43 after a single administration [5].

What the Published Literature Reports

Rodent studies

In obese mice, LY3437943 decreased body weight and improved glycemic control [5]. The earlier triagonist from Finan and colleagues, a related but different peptide, outperformed existing dual co-agonists and mono-agonists in reducing body weight, improving glycemic control and reversing hepatic steatosis in rodent models [2].

Phase 2 obesity trial

In a 48-week, double-blind, placebo-controlled phase 2 trial, 338 adults with obesity, or with overweight plus at least one weight-related condition, were randomized to one of several retatrutide dose levels or placebo [1]. At the 24-week primary end point, least-squares mean body-weight change reached -17.5% in the highest-dose group versus -1.6% with placebo. At 48 weeks the change ranged from -8.7% in the lowest-dose group to -24.2% in the highest, versus -2.1% with placebo. The most common adverse events were gastrointestinal, dose-related and mostly mild to moderate, and dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter [1].

Phase 2 type 2 diabetes trial

A parallel phase 2 trial randomized 281 adults with type 2 diabetes at 42 U.S. centres to retatrutide, placebo or the GLP-1R agonist dulaglutide [4]. At 24 weeks, HbA1c fell by up to 2.02 percentage points with retatrutide, versus 0.01 with placebo and 1.41 with dulaglutide. At 36 weeks, body weight decreased by up to 16.94% with retatrutide, versus 3.00% with placebo and 2.02% with dulaglutide. No severe hypoglycaemia was reported [4].

Liver fat substudy

A substudy of the obesity trial followed 98 participants with metabolic dysfunction-associated steatotic liver disease and at least 10% liver fat [7]. Mean relative change in liver fat at 24 weeks ranged from -42.9% in the lowest-dose group to -82.4% in the highest, versus +0.3% with placebo, and up to 86% of participants in the highest-dose group reached normal liver fat (below 5%), versus none on placebo. The liver-fat reductions tracked changes in body weight, abdominal fat, and metabolic measures of insulin sensitivity and lipid metabolism [7].

These figures are findings of controlled clinical trials of investigational retatrutide, conducted in selected populations under medical supervision. They describe that molecule in those settings. They are not properties of any research material and not outcomes to be expected outside a trial.

Open Research Questions

• Receptor attribution in humans: rodent loss-of-function work assigned the energy-expenditure effect to the glucagon receptor [2], but how much each receptor contributes to the weight and liver-fat changes seen in trials has not been partitioned.
• Glucagon and glycemia: Glucagon's classical role is to raise blood glucose [9], yet HbA1c fell substantially in the diabetes trial [4]. How the incretin components offset glucagon's glycemic pull across tissues and metabolic states remains an active question [2, 9].
• Heart rate: the obesity trial recorded dose-dependent heart-rate increases that peaked at 24 weeks and then declined [1]. The receptor source and mechanism are not established.
• Hepatic mechanism: liver-fat reductions were related to weight loss [7]. Whether direct hepatic GCGR signaling contributes independently of weight loss is still open.
• Optimal receptor ratios: a 2025 medicinal chemistry study reported triple agonists with much weaker GIPR activity that matched retatrutide's metabolic efficacy in the authors' preclinical experiments, suggesting potent activation of all three receptors may not be required [12].

Laboratory Handling and Storage

RT-3 is supplied as a white lyophilized powder with a specified storage temperature of -20°C. A few practical points apply to acylated incretin-class peptides in general.

• Keep lyophilized material sealed at -20°C, protected from light and moisture, and let the vial reach room temperature before opening so condensation does not form on the powder.
• Reconstitute in a solvent suited to the assay (the specification lists sterile water), then divide into single-use aliquots so the stock is not repeatedly frozen and thawed. Label each aliquot with concentration, solvent, date and lot.
• Lipidated peptides can adsorb to some plastics, so low-binding tubes and verification of working concentrations are worth the effort.
• Plan for albumin. Because the fatty diacid drives albumin binding, serum or BSA in the medium will shift apparent potency. In the tirzepatide discovery work, in-vitro binding and cAMP assays were run without albumin so the analogue could be compared directly with native hormones [11].
• When attributing a response to one receptor, include native GLP-1, GIP and glucagon as reference ligands and, where possible, receptor-selective antagonists or knockout systems, following the loss-of-function approach of the original triagonist work [2].

Every batch of RT-3 is independently third-party tested. Certificates for lot RT10001 (10mg, 99.87% purity) and lot RT30001 (30mg, 99.71% purity), both tested in August 2026, are published on our COA page. RT-3 does not ship with a printed certificate; the published certificate is the record.